1310 related articles for article (PubMed ID: 28993732)
1. Purinergic Signalling: Therapeutic Developments.
Burnstock G
Front Pharmacol; 2017; 8():661. PubMed ID: 28993732
[TBL] [Abstract][Full Text] [Related]
2. Purinergic Signalling and Neurological Diseases: An Update.
Burnstock G
CNS Neurol Disord Drug Targets; 2017; 16(3):257-265. PubMed ID: 27658510
[TBL] [Abstract][Full Text] [Related]
3. Purine and purinergic receptors.
Burnstock G
Brain Neurosci Adv; 2018; 2():2398212818817494. PubMed ID: 32166165
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic potential of purinergic signalling.
Burnstock G
Biochem Pharmacol; 2018 May; 151():157-165. PubMed ID: 28735873
[TBL] [Abstract][Full Text] [Related]
5. Molecular pharmacology of P2Y receptor subtypes.
von Kügelgen I
Biochem Pharmacol; 2021 May; 187():114361. PubMed ID: 33309519
[TBL] [Abstract][Full Text] [Related]
6. Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets.
Jacobson KA; IJzerman AP; Müller CE
Biochem Pharmacol; 2021 May; 187():114311. PubMed ID: 33130128
[TBL] [Abstract][Full Text] [Related]
7. Introduction to Purinergic Signaling.
Burnstock G
Methods Mol Biol; 2020; 2041():1-15. PubMed ID: 31646477
[TBL] [Abstract][Full Text] [Related]
8. Purinergic receptors modulators: An emerging pharmacological tool for disease management.
Mahmood A; Iqbal J
Med Res Rev; 2022 Jul; 42(4):1661-1703. PubMed ID: 35561109
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes.
von Kügelgen I
Pharmacol Ther; 2006 Jun; 110(3):415-32. PubMed ID: 16257449
[TBL] [Abstract][Full Text] [Related]
10. Medicinal chemistry of adenosine, P2Y and P2X receptors.
Jacobson KA; Müller CE
Neuropharmacology; 2016 May; 104():31-49. PubMed ID: 26686393
[TBL] [Abstract][Full Text] [Related]
11. New paradigms in purinergic receptor ligand discovery.
Jacobson KA; Pradhan B; Wen Z; Pramanik A
Neuropharmacology; 2023 Jun; 230():109503. PubMed ID: 36921890
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology and structure of P2Y receptors.
von Kügelgen I; Hoffmann K
Neuropharmacology; 2016 May; 104():50-61. PubMed ID: 26519900
[TBL] [Abstract][Full Text] [Related]
13. Potential therapeutic targets in the rapidly expanding field of purinergic signalling.
Burnstock G
Clin Med (Lond); 2002; 2(1):45-53. PubMed ID: 11871639
[TBL] [Abstract][Full Text] [Related]
14. Agonists and Antagonists for Purinergic Receptors.
Müller CE; Baqi Y; Namasivayam V
Methods Mol Biol; 2020; 2041():45-64. PubMed ID: 31646479
[TBL] [Abstract][Full Text] [Related]
15. Introductory overview of purinergic signalling.
Burnstock G
Front Biosci (Elite Ed); 2011 Jun; 3(3):896-900. PubMed ID: 21622101
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of P2Y receptors.
von Kügelgen I
Brain Res Bull; 2019 Sep; 151():12-24. PubMed ID: 30922852
[TBL] [Abstract][Full Text] [Related]
17. Physiopathological roles of P2X receptors in the central nervous system.
Burnstock G
Curr Med Chem; 2015; 22(7):819-44. PubMed ID: 25005189
[TBL] [Abstract][Full Text] [Related]
18. Purinergic signalling: past, present and future.
Burnstock G
Braz J Med Biol Res; 2009 Jan; 42(1):3-8. PubMed ID: 18853040
[TBL] [Abstract][Full Text] [Related]
19. G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions.
Jacobson KA; Balasubramanian R; Deflorian F; Gao ZG
Purinergic Signal; 2012 Sep; 8(3):419-36. PubMed ID: 22371149
[TBL] [Abstract][Full Text] [Related]
20. Purinergic signalling in brain ischemia.
Pedata F; Dettori I; Coppi E; Melani A; Fusco I; Corradetti R; Pugliese AM
Neuropharmacology; 2016 May; 104():105-30. PubMed ID: 26581499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
